 0 Table of Contents |
  1 Home |
  2 Implementation |
  3 Examples Overview |
  4 Persona 1 - Clinical Trials Patient |
  5 Persona 2 - Standard of Care Patient |
  6 Downloads |
  7 Change log |
  8 Artifacts Summary |
   8.1 CTC Adverse Event |
   8.2 Adverse Event Expectation |
   8.3 Adverse Event Participant |
   8.4 Adverse Event Resolved Date |
   8.5 Adverse Event Seriousness Outcome |
   8.6 CTC Adverse Event Grade |
   8.7 Adverse Event Expectation Value Set |
   8.8 Adverse Event Participant Function |
   8.9 Adverse Event Relatedness Value Set |
   8.10 Adverse Event Seriousness Outcome Value Set |
   8.11 Adverse Event Seriousness Value Set |
   8.12 CTCAE Grade Value Set |
   8.13 CTCAE Terms Value Set |
   8.14 CTCAE Grade Code System |
   8.15 ctc-adverse-event-example-1 |
   8.16 ctc-adverse-event-example-2 |
   8.17 ctc-adverse-event-example-3 |
   8.18 patient-example-kaitlyn-b |
   8.19 PatientPersona2 |
   8.20 PractitionerExample1 |
   8.21 ae-bundle-kaitlyn-compass-trial |
   8.22 ae-bundle-persona-2 |
   8.23 Alliance COMPASS Trial A011801 |
   8.24 cancer-related-medication-request-doxorubicin2-persona-2 |
   8.25 ctc-adverse-event-anemia1-persona-2 |
   8.26 ctc-adverse-event-anemia2-persona-2 |
   8.27 ctc-adverse-event-compass-ex1 |
   8.28 ctc-adverse-event-compass-ex1a |
   8.29 ctc-adverse-event-compass-ex1b |
   8.30 ctc-adverse-event-compass-ex2 |
   8.31 ctc-adverse-event-nausea1-persona-2 |
   8.32 ctc-adverse-event-neutropenia1-persona-2 |
   8.33 ctc-adverse-event-neutropenia2-persona-2 |
   8.34 diagnosticreport-cbc-201-1-persona2 |
   8.35 diagnosticreport-cbc-202-1-persona2 |
   8.36 encounter-ae1-evaluation-persona2 |
   8.37 kaitlyn-primary-cancer-condition-ex1 |
   8.38 medadmin-doxorubicin-persona-2 |
   8.39 medication-administration-kadcyla |
   8.40 medication-administration-tucatinib |
   8.41 medication-request-example-kadcyla |
   8.42 medication-request-example-tucatinib |
   8.43 medrequest-doxorubicin-persona-2 |
   8.44 OrganizationExample1 |
   8.45 practitioner-oncology-nurse-jane |
   8.46 primary-cancer-condition-persona-2 |
   8.47 r201-1 |
   8.48 r201-10 |
   8.49 r201-11 |
   8.50 r201-12 |
   8.51 r201-13 |
   8.52 r201-14 |
   8.53 r201-15 |
   8.54 r201-16 |
   8.55 r201-17 |
   8.56 r201-2 |
   8.57 r201-3 |
   8.58 r201-4 |
   8.59 r201-5 |
   8.60 r201-6 |
   8.61 r201-7 |
   8.62 r201-8 |
   8.63 r201-9 |
   8.64 r202-1 |
   8.65 r202-10 |
   8.66 r202-11 |
   8.67 r202-12 |
   8.68 r202-13 |
   8.69 r202-14 |
   8.70 r202-15 |
   8.71 r202-16 |
   8.72 r202-17 |
   8.73 r202-2 |
   8.74 r202-3 |
   8.75 r202-4 |
   8.76 r202-5 |
   8.77 r202-6 |
   8.78 r202-7 |
   8.79 r202-8 |
   8.80 r202-9 |
   8.81 Standard of Care Protocol 0U812 |
   8.82 us-core-organization-acme-laboratory |
   8.83 us-core-organization-physician-services-inc |
   8.84 us-core-practitioner-nancy-oncology-nurse |
   8.85 us-core-practitioner-owen-oncologist |